Stocklytics Platform
Corcept Therapeutics
CORT88
$71.94arrow_drop_up5.78%$4.00
NASDAQ - As of Apr 24, 4:01 PM EDT Market Closed
High Quality
High Growth
CORT88

$71.94

arrow_drop_up5.78%

Performance History

Chart placeholder
Key Stats
Open$69.22
Prev. Close$69.27
EPS1.23
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$7.25B
PE Ratio58.49
LOWHIGH
Day Range67.92
76.14
52 Week Range20.84
118.46
Ratios
P/B Ratio9.40
Revenue$675.04M
Operating M. %13.89%
Earnings$141.20M
Earnings Growth %33.04%
EBITDA Margin %20.41%
ROE %23.81%
EPS1.23

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Eli Lilly & Co
LLY84
Price$860.07
Perf. (24h)arrow_drop_up3.67%$30.48
Market Cap$744.96B
UnitedHealth Group
UNH69
Price$424.49
Perf. (24h)arrow_drop_down0.61%-$2.63
Market Cap$548.34B
Johnson & Johnson
JNJ61
Price$154.91
Perf. (24h)arrow_drop_down0.28%-$0.43
Market Cap$371.98B
AbbVie
ABBV67
Price$180.41
Perf. (24h)arrow_drop_up1.85%$3.28
Market Cap$303.69B

About Corcept Therapeutics (CORT)

Corcept Therapeutics Inc (CORT) is a pharmaceutical company that specializes in the development and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. The company focuses on discovering and developing small molecule drugs that selectively modulate the effects of cortisol. Corcept's lead product, Korlym, is an oral medication that is approved for the treatment of hyperglycemia in patients with endogenous Cushing's syndrome. The company is also conducting clinical trials to evaluate the use of Korlym in the treatment of various types of cancer, including ovarian, lung, and pancreatic cancer.
In terms of stock performance, Corcept Therapeutics Inc has had a relatively stable history. Over the past five years, the stock price has fluctuated between a low of $7.50 and a high of $25.00. Currently, the stock is trading around $15.00. The market capitalization of Corcept Therapeutics Inc is approximately $1.5 billion. The company has a PEG ratio of 1.42, indicating that the stock may be slightly overvalued compared to its industry peers. However, it is important to note that the biopharmaceutical industry as a whole tends to have higher valuations due to the high-risk nature of drug development. Corcept Therapeutics Inc is also trading below its 52-week high of $24.00, suggesting that there may be potential for price appreciation in the future.
Show more
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Joseph K. Belanoff M.D.
Headquarters
Menlo Park
Employees
299
Exchange
NASDAQ
add Corcept Therapeutics to watchlist

Keep an eye on Corcept Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Corcept Therapeutics 's (CORT) price per share?

The current price per share for Corcept Therapeutics (CORT) is $71.95. The stock has seen a price change of $4.01 recently, indicating a 5.78% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Corcept Therapeutics (CORT)?

For Corcept Therapeutics (CORT), the 52-week high is $118.46, which is 64.65% from the current price. The 52-week low is $20.84, the current price is 245.24% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Corcept Therapeutics (CORT) a growth stock?

Corcept Therapeutics (CORT) has shown an average price growth of -1.65% over the past three years. It has received a score of 88 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Corcept Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Corcept Therapeutics (CORT) stock price performance year to date (YTD)?

As of the latest data, Corcept Therapeutics (CORT) has a year-to-date price change of 42.78%. Over the past month, the stock has experienced a price change of 20.98%. Over the last three months, the change has been 15.5%. Over the past six months, the figure is 49.7%. Looking at a longer horizon, the five-year price change stands at 466.97%.
help

Is Corcept Therapeutics (CORT) a profitable company?

Corcept Therapeutics (CORT) has a net income of $141.21M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 13.89% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $675.04M, with a revenue growth rate of 39.94%, providing insight into the company's sales performance and growth. The gross profit is $664.16M. Operating income is noted at $136.95M. Furthermore, the EBITDA is $138.29M.
help

What is the market capitalization of Corcept Therapeutics (CORT)?

Corcept Therapeutics (CORT) has a market capitalization of $7.26B. The average daily trading volume is 73.66, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level